+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Exact Sciences Corp (EXAS) - Product Pipeline Analysis, 2022 Update

1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Exact Sciences Corp (Exact Sciences) is a molecular diagnostic company that focuses on the development of tests for various types of cancers. The company’s flagship product, Cologuard test is a US FDA-approved non-invasive stool-based deoxyribonucleic acid (DNA) screening product indicated for the early detection of colorectal cancer and pre-cancer. It uses a multi-target approach to detect DNA and hemoglobin biomarkers related to colorectal cancer. The company also offers Oncotype DX gene expression tests for prostate, breast, and colon cancers; and Oncotype DX AR-V7 Nucleus Detect test, a liquid-based test designed for advanced stage prostate cancer. It operates manufacturing and laboratory facilities in Madison, Wisconsin to process Cologuard tests. Exact Sciences is headquartered in Madison, Wisconsin, the US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.


  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company Exact Sciences Corp
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

  • Exact Sciences Corp Company Overview
  • Exact Sciences Corp Company Snapshot
  • Exact Sciences Corp Pipeline Products and Ongoing Clinical Trials Overview
  • Exact Sciences Corp - Pipeline Analysis Overview
  • Business Description
  • Exact Sciences Corp

Companies Mentioned

A selection of companies mentioned in this report includes:

  • CellMax, Inc.
  • Freenome Inc
  • Natera Inc
  • StageZero Life Sciences Ltd
  • Cambridge Epigenetix Ltd
  • Nucleix Ltd
  • Lineage Cell Therapeutics Inc
  • EDP Biotech Corporation
  • Grail Inc
  • Epigenomics AG